Synthesis and structural characterization of a mimetic membrane-anchored prion protein by Hicks, M R et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis and structural characterization of a mimetic
membrane-anchored prion protein
Citation for published version:
Hicks, MR, Gill, AC, Bath, IK, Rullay, AK, Sylvester, ID, Crout, DH & Pinheiro, TJT 2006, 'Synthesis and
structural characterization of a mimetic membrane-anchored prion protein' Febs Journal, vol 273, no. 6, pp.
1285-1299., 10.1111/j.1742-4658.2006.05152.x
Digital Object Identifier (DOI):
10.1111/j.1742-4658.2006.05152.x
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Preprint (usually an early version)
Published In:
Febs Journal
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
 
Synthesis and structural characterization of a GPI-
anchored prion protein 
Matthew R. Hicks1, Andrew C. Gill2, Imanpreet K. Bath1, Atvinder K. Rullay3, 
Ian D. Sylvester2, David H. Crout3 and Teresa J. T. Pinheiro1 
 
1 Department of Biological Sciences, Gibbet Hill Road, University of Warwick, Coventry 
CV4 7AL, UK 
2 Institute for Animal Health, Compton, Newbury, Berks, RG20 7NN, UK 
3 Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK 
 
Keywords 
Prion protein; GPI-anchored prion; membranes; prion conversion; rafts; structure 
 
Correspondence  
Teresa JT Pinheiro, Department of Biological Sciences, University of Warwick, Coventry 
CV4 7AL, UK; Tel: +44 (0) 2476 528364; Fax: +44 (0) 2476 523701; E-mail: 
t.pinheiro@warwick.ac.uk 
 
 
 
Running title: Lipid-anchored PrP 
 
 1
Abstract 
During pathogenesis of transmissible spongiform encephalopathies (TSEs), an 
abnormal form (PrPSc) of the host encoded prion protein (PrPC) accumulates in insoluble 
fibrils and plaques. The two forms of PrP appear to have identical covalent structures, 
but differ in secondary and tertiary structure. Both PrPC and PrPSc have 
glycosylphospatidylinositol (GPI) anchors through which the protein is tethered to cell 
membranes. Membrane attachment has been suggested to play a role in the conversion 
of PrPC to PrPSc, but the majority of in vitro studies of the function, structure, folding and 
stability of PrP have focused on use of recombinant protein lacking the GPI anchor. In 
order to study the effects of membranes on the structure of PrP, we have synthesised a 
GPI anchor mimetic (GPIm), which we have covalently coupled to a genetically 
engineered cysteine residue at the C-terminus of recombinant PrP. We demonstrate that 
PrP coupled to GPIm (PrP-GPIm) inserts into model lipid membranes and that structural 
information can be obtained from this membrane-anchored PrP. We show that the 
structure of PrP is not perturbed when PrP-GPIm is reconstituted in phosphatidylcholine 
and raft membranes. The results provide experimental evidence in support of previous 
suggestions that NMR structures of soluble, anchor-free forms of PrP represent the 
structure of cellular, membrane-anchored PrP. The availability of a GPI-anchored 
construct of PrP provides a unique model to investigate the effects of different lipid 
environments on the structure and conversion mechanisms of PrP. 
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Abbreviations: DPPC, Dipalmitoyl phosphatidylcholine; MES, 2-(N-morpholino) 
ethanesulphonic acid; MOPS, 3-(N-morpholino) propanesulphonic acid; OG, octyl-β-D-
glucopyranoside; POPC, 1-palmitoyl-2-oleoyl-phosphatidylcholine; PrP, Prion protein; 
PrP-S231C, recombinant Syrian Hamster prion protein, residues 23-231 (preceded by a 
methionine start codon) with Ser231 mutated to Cys; PrP-Glut, PrP-S231C with a 
disulfide bond between Cys 179 and Cys 214 and with a glutathione group disulfide-
bonded to Cys 231; PrP-React, PrP-S231C with a disulfide bond between Cys 179 and 
Cys 214 and with Cys 231 reduced; PrP-GPIm, PrP-S231C with a disulfide bond 
between Cys 179 and Cys 214 and with a GPI mimetic disulfide bonded to Cys 231. 
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Introduction 
Transmissible spongiform encephalopathies are a family of fatal, neurodegenerative 
diseases that includes scrapie of sheep, bovine spongiform encephalopathy (BSE) of 
cattle, chronic wasting disease (CWD) in cervids and Creutzfeldt-Jakob disease (CJD) in 
humans. These diseases are characterised by astrocytic gliosis, neuronal apoptosis and 
deposition of an abnormally folded isoform of the host encoded prion protein, PrPC [1]. 
PrPC is a small, cell surface glycoprotein, which is soluble in detergents and is protease-
sensitive [2]. By contrast, the abnormal form, PrPSc, is insoluble in detergents and 
partially protease resistant, leading to accumulation of the protein in amyloid plaques 
and fibrils during disease. PrPSc is also believed to constitute the majority, if not all of the 
infectious agent in TSE diseases [3, 4].  
PrPC is translated as a polypeptide of around 250 amino acids (depending on 
species) and contains two signal peptides, which are cleaved during post-translational 
processing [5]. An N-terminal signal peptide directs the protein to the endoplasmic 
reticulum (ER) for export, via the secretory pathway, to the outer leaflet of the plasma 
membrane, where it is anchored through a glycosylphospatidylinositol (GPI) anchor. 
Attachment of the GPI anchor to the C-terminus of PrP occurs in the ER by a 
transamidation reaction, following proteolytic cleavage of the C-terminal signal peptide. 
During post translational processing in the secretory pathway, PrPC can also be N-
glycosylated with diverse oligosaccharides at two asparagine residues, towards the C-
terminal end [6], and a single disulfide bond is formed, also towards the C-terminus [1].  
Initial studies of the structure of PrPC and PrPSc were carried out by Fourier 
transform infra red (FTIR) spectroscopy and indicated that PrPC is composed of around 
 4
35% α-helix and a small amount of β-sheet, whereas PrPSc appears to have elevated 
levels of β-sheet [7, 8]. Higher resolution studies of PrPC structure have made use of 
NMR and X-ray crystallographic methods, but have focused almost entirely on analysis 
of recombinant forms of the protein that lack the lipid anchor and glycosylation. These 
studies show that PrP has a folded, C-terminal domain, comprising approximately half of 
the protein’s amino acid sequence [9, 10]. This folded domain contains predominantly α-
helical structure with a small amount of β-sheet, in line with the early FTIR studies of 
PrPC. The N-terminal half of the protein appears to be flexible and disordered and 
contains four octa-peptide-repeat regions, which have been shown to bind copper ions 
[11-14]. The structure of recombinant PrP is assumed to represent the cellular form of 
PrP. A recent report on the structure of PrPC purified from healthy calf brains further 
supports this assumption [15]. In this study the protein is natively folded and retains the 
two glycosyl moieties but is cleaved from the GPI anchor and therefore released from 
the membrane surface.  
There is no high-resolution structure of PrPSc, but models have been constructed 
based initially on accessibility of antibody-binding epitopes and, more recently, on 
electron crystallographic measurements. The best current models suggest that PrPSc 
adopts parallel β-sheet structures with the PrP sequence from residues 89-175 forming 
a trimeric β-helical conformation, whilst the C-terminal region (residues 176-227) retains 
the disulfide-linked, α-helical conformation present in PrPC [16, 17].  
The normal cell biology of PrPC involves rapid, constitutive endocytosis from the 
plasma membrane [18], an event which requires interaction with additional cell surface 
molecules. Like other GPI-anchored proteins, PrPC occupies specialised domains on the 
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cell surface known as lipid rafts [19], but appears to move out of these rafts prior to 
endocytosis [20]. The conversion from PrPC to PrPSc is thought to take place either on 
the cell surface [21-23] perhaps in lipid rafts [19, 24-28], or during internal transit in the 
endocytic pathway [27, 29-31]. It is also thought that partial unfolding is necessary, 
potentially assisted by accessory molecules. If the conversion is indeed a cell surface 
event, this requires a thorough understanding of the folding and interactions of PrP in its 
tethered conformation on the plasma membrane.  
The interaction of PrP with different lipid components is complex and is not 
completely understood. Previously, we have shown that anchorless forms of PrP bind to 
lipid membranes [32-34]. This interaction involves both an electrostatic and a 
hydrophobic component. The composition of the membranes and conformation of PrP 
affect the strength of the binding and the propensity for aggregation of the protein. It was 
found that membranes can be disrupted by PrP under certain conditions [34]. Also, 
whereas some membranes lead to extensive aggregation or fibrillization of PrP, other 
membranes appear to provide protection against conversion [34, 35].  
To date, most structural studies have been carried out on protein that does not 
contain a lipid anchor. However, as outlined above, there is considerable evidence that 
membrane anchored forms of PrP are involved in the pathological conversion process. 
In order to study the structure of PrP in a context closer to that found in vivo, we have 
synthesised a GPI-mimetic (GPIm) that can be coupled to the C-terminus of PrP by 
reaction with the free thiol group of a genetically engineered cysteine residue. Coupling 
of GPIm to PrP occurs via a disulfide bond formed by nucleophilic attack, by the thiolate 
anion of the cysteine side chain, on the methane thiosulphonate group of GPIm. The 
resulting lipid-modified PrP molecule (PrP-GPIm) was reconstituted into different model 
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membranes (Fig. 1). The structure of PrP-GPIm inserted in lipid membranes was studied 
by infrared spectroscopy. The lipid composition of the membrane was chosen to 
represent the cellular environments in which the protein is found in vivo, such as inside 
or outside lipid rafts.  
Results 
A previous report by Eberl et al. [36] detailed the characterisation of recombinant PrP 
inserted in lipid membranes. This protein had a hydrophilic C-terminal extension of five 
glycines and a cysteine residue, which was coupled to a thiol-reactive lipid, PDP-DHPE 
(N-((2-pyridyldithio)-propinyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine). 
We have used a similar principle to covalently attach a synthetic GPI analogue to the 
thiol group of an engineered cysteine at the C-terminus of PrP, taking a somewhat 
different strategy. A cysteine residue replaces serine 231, where the natural GPI anchor 
is coupled to PrP, and we used a synthetic GPI analogue, which carries a linker region 
based on ethylene-glycol units (Rullay, Hicks, Pinheiro and Crout, in preparation). This 
linker places the protein at a distance from the membrane surface similar to that 
provided by the glycan moiety in the reported natural GPI anchor [37]. Several steps are 
required to couple the lipid anchor to PrP-S231C. During these steps, it is essential to 
maintain the single internal disulfide bond in PrP, whilst producing a free thiol moiety at 
the C-terminal cysteine.  
Expression, purification and refolding of PrP-S231C 
The C-terminal serine residue of Syrian hamster PrP was altered genetically to a 
cysteine residue by site-directed mutagenesis to produce the construct SHaPrP-S231C. 
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The protein was expressed in insoluble inclusion bodies by recombinant BL21Star E. 
coli and was solubilized and purified by size exclusion chromatography followed by 
reversed phase HPLC. After lyophilization, the protein was resuspended in an oxidation 
buffer containing both oxidised and reduced glutathione using a method modified from 
Mo et al. [38]. This reaction produced primarily monomeric PrP containing a single, 
native, internal disulfide bond with the C-terminal Cys231 protected by a glutathione 
molecule. This was confirmed by on line HPLC-mass spectrometric (HPLC-MS) analysis 
(Fig. 2A).  
The equivalent PrP Cys mutant, PrP(Gly)6Cys, of Eberl et al. [36] was refolded by 
disulfide oxidation on Ni-NTA columns, followed by selective reduction of disulfides in 
the resulting dimeric species. We attempted the method described in Eberl et al., but 
found that glutathione mediated re-oxidation formed the correct product more 
specifically and in significantly higher yields. The glutathione protecting group was 
removed by brief treatment with DTT, the resulting product was purified by HPLC (Fig. 
2B) and was found by HPLC-MS analysis to have an intact internal disulfide bond and a 
reduced C-terminal cysteine (Cys 231) (Fig. 2C). This process created a reasonable 
yield of the correctly folded PrP molecule with a free thiol at Cys 231, which we refer to 
as PrP-React.  
Coupling of PrP-React to GPIm  
We have synthesised a mimetic of a glycosylphospatidylinositol membrane anchor, 
GPIm, and the details of this synthesis are the subject of a different manuscript (Rullay, 
Hicks, Pinheiro and Crout, in preparation). GPIm carries a reactive methane 
thiosulphonate group, which reacts with the thiolate anion of cysteine residues (see 
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Materials and Methods, Scheme 1). In trial coupling reactions, we determined that the 
efficiency of the coupling reaction is dependent on several factors. These include the 
solubility of both GPIm and PrP-React, temperature, pH, the reaction time and the ionic 
strength of the solution. Optimum solubility of lipids, such as GPIm, is typically achieved 
by use of organic solvents. Several solvents were investigated, including ethanol, 
methanol and DMSO, giving similar results. The solubility of GPIm at different ethanol 
concentrations is shown is Fig. 3A. Concentrations above 60% (v/v) ethanol in water 
were required to maintain GPIm in solution, and, consequently, allowed the coupling 
reaction to proceed at acceptable yields (Fig. 3B). The reaction should also proceed 
more rapidly at a higher pH, under which conditions the proportion of cysteine that is in 
the reactive, anionic form will be increased. However, we found that increasing the pH of 
the reaction buffer resulted in a decrease in the yield, probably due to decreased 
solubility of PrP-React in water/ethanol at high pH. It is also possible that the two 
positively charged arginine residues adjacent to Cys 231 in the primary structure of PrP 
may lower the effective pKa of the cysteine side chain by stabilising the negatively 
charged thiolate anion, thereby helping the reaction to proceed at lower pH. Our final 
empirically-determined reaction protocol involves the use of 70% (v/v) ethanol in water, 
10-fold molar excess of GPIm and incubation at room temperature for 2 hours. The use 
of buffer (MES or MOPS) even at low concentrations (2 mM) resulted in a decrease in 
the yield (data not shown). This was probably due to a decrease in the solubility of the 
protein in ethanolic solutions in the presence of salts. For this reason, buffers were not 
added to the  the coupling reactions. The pH of the solutions was measured and found 
to be approximately pH 6. Typically, 0.5 mg of PrP-GPIm were obtained per mg of PrP-
React. Correctly formed product, PrP-GPIm, was separated from non-coupled PrP-
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React by RP-HPLC (Fig. 4A) and the molecular weight of the product was confirmed by 
HPLC-MS (Fig. 4B).  
Reconstitution of PrP-GPIm into membranes 
PrP-GPIm was anchored in lipid membranes through the insertion of the hydrocarbon 
chains of GPIm into the lipid bilayer. Several methods are commonly used to 
reconstitute integral membrane proteins and GPI-anchored proteins into membranes 
[39, 40]. Our approach was to pre-form liposomes, partially disrupt them with detergent 
and mix with PrP-GPIm. Upon detergent removal, liposomes are re-formed, in which 
PrP-GPIm is anchored.  
The concentration of the detergent octyl-β-D-glucopyranoside (OG) required to 
induce a phase break in the liposomes was determined by titration of a concentrated 
stock of OG into a suspension of liposomes [39]. The turbidity was monitored at 350 nm 
and solubility curves identified for both 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) 
and raft liposomes (Fig. 5). The concentration of OG at the midpoint of the transition was 
found to be 22 mM for POPC and 28 mM for rafts at 20 °C.  
After detergent dialysis, reconstituted liposomes containing PrP-GPIm were 
separated on sucrose gradients and analysed by SDS-PAGE (see Materials and 
Methods). Eight fractions spanning the entire sucrose gradient were collected and the 
lipid was visible as a turbid band in the top three fractions for POPC samples and mainly 
in fraction 3 for raft samples. The majority of PrP-GPIm co-migrated with the liposomes 
(Fig. 6). The fraction of PrP-GPIm that was associated with the liposomes was assessed 
by densitometry of the bands on the SDS-PAGE gels in the first three lanes as a 
percentage of the total across all eight sample lanes. Reconstitution efficiencies 
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appeared independent of pH and were ~ 90% for POPC liposomes and ~ 70% for raft 
liposomes.  
Structure of PrP-GPIm in liposomes 
The structures of PrP-GPIm and wild type PrP (PrP-WT) in solution were probed by 
circular dichroism (CD) and attenuated total reflection (ATR) FTIR. The far-UV CD 
spectrum of PrP-WT shows the typical minima around 208 and 222 nm (Fig. 7A) 
associated with proteins containing predominantly α-helical structure. In contrast, the CD 
spectrum of PrP-GPIm shows a single broad minimum around 214 nm and a 
characteristic loss in signal intensity, which are associated with β-sheet structure. These 
spectral properties indicate that PrP-GPIm in solution has an elevated content of β-sheet 
relative to PrP-WT. These results are consistent with the spectral changes observed by 
ATR FTIR. The amide I region of the FTIR spectrum for PrP-GPIm and PrP-WT is 
shown in Fig. 7B. The amide I band arises mainly from stretching modes of the 
backbone carbonyl bonds in the protein. The positions of absorbance bands are 
dependent on secondary structure and, therefore, can be used to measure the amount 
of different types of secondary structure in proteins. Since the bands overlap it is 
necessary to use peak fitting analysis to deconvolute the contributions from different 
secondary structural components. The amide I band of PrP-WT in solution is centered 
around 1645 cm−1 due to the contribution from both random coil (30%) and α-helical 
structure (32%). There are also contributions from β-sheet (21%) and β-turns (17%). 
Although the levels of β-sheet measured here are greater than the level predicted from 
NMR structures of the folded C-terminal domain of PrP (residues 90−231) [41], the 
differences may be attributable to the adoption of a β-sheet-like extended structure by 
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the N-terminal region of PrP comprising residues 23−90 upon deposition on the ATR 
crystal. Although the N-terminal region is traditionally thought of as flexible and 
unstructured, several recent papers have indicated that stable, extended structures are 
present within this domain [42-44]. The ATR FTIR spectrum of PrP-GPIm in solution is 
distinct from that of PrP-WT (Fig. 7B). Secondary structure calculations suggest that 
PrP-GPIm in solution has a higher content of β-sheet compared with the anchorless 
protein (PrP-GPIm has 37% β-sheet compared with 21% in PrP-WT) at the expense of 
α-helix (32% in PrP-GPIm, 19% in PrP-WT) and some random coil (30% in PrP-GPIm, 
23% in PrP-WT).  
After insertion of PrP-GPIm into membranes, ATR FTIR spectra were acquired for 
POPC and raft membranes containing PrP-GPIm at pH 5 and pH 7. The amide I region 
of the ATR FTIR spectrum for PrP-GPIm inserted in POPC and raft membranes, at pH 
5, is shown in Fig. 7B. Insertion of PrP-GPIm into lipid membranes returns the structure 
of PrP to the original α-helical structure of PrP-WT. Similar spectra were observed for 
reconstituted PrP-GPIm at pH 7 (data not shown). The secondary structure content, 
estimated from peak fitting analysis, was found to be very similar to that of PrP-WT. 
These results indicate that PrP-GPIm in POPC and raft membranes have a very similar 
structure and demonstrate that the structure of PrP in these membranes resembles the 
structure of anchorless protein in solution. 
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Discussion 
Membrane-anchored PrP has a similar structure to soluble anchorless PrP 
There are several published methods by which lipid anchored proteins can be 
reconstituted into liposomes. Reconstitution of proteins into membranes for subsequent 
structural or functional studies requires that the method used does not perturb the native 
structure of the protein irreversibly. Most methods involve the use of detergent, which 
can often adversely affect protein structure [39]. The best method for the reconstitution 
of a particular protein often has to be determined empirically.  
We attempted various methods for reconstituting PrP-GPIm into membranes. 
Spontaneous insertion of the lipid-anchored protein into pre-formed liposomes did not 
occur; this may be due to a low partition energy between PrP-GPIm in solution and PrP-
GPIm anchored in the membrane. Two observations are consistent with this 
interpretation: firstly, the lipid-modified protein (PrP-GPIm) was readily soluble in water 
and secondly, the structure of PrP-GPIm in solution was altered relative to the 
anchorless protein (PrP-WT) (Fig. 7). The latter suggests an interaction of the lipid 
anchor with the protein in the absence of membranes, which may explain why 
spontaneous membrane insertion of PrP-GPIm was not observed. However, the use of 
OG promoted the insertion of PrP-GPIm into liposomes, producing a membrane-
reconstituted protein in which the normal, α-helical structure of PrP is restored (Fig. 7B).  
Solution NMR structures of various recombinant forms of prion proteins, all lacking 
a GPI anchor, have been proposed to represent the structure of the cellular form of PrP 
anchored in the cell membrane [41, 45, 46]. Furthermore, molecular dynamic 
calculations revealed that the glycan region in the natural GPI of PrP was highly flexible 
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[47] which led to the speculation that PrP could adopt a wide range of orientations 
relative to the plane of the cell membrane. Some of these orientations would allow the 
possibility of direct interactions of the protein with the membrane surface, which could 
lead to a different protein structure relative to the reported structures of anchorless PrP 
in solution. To test these possibilities, membrane reconstitution of a lipid-anchored form 
of PrP is imperative. 
Reconstitution of PrP-GPIm in two types of model membranes, POPC and raft 
membranes, at either pH 7 or 5, resulted in a conformation of PrP that resembles the 
anchorless protein in solution. Similar findings were reported by Eberl et al. [36] with an 
alternate membrane-anchored PrP construct. In both Eberl’s and the present lipid-
modified PrP constructs, the prion protein is placed at a distance from the membrane 
surface via a linker region which mimics that provided by the flexible glycan moiety of 
the natural GPI anchor in PrP. In the PrP construct of Eberl et al., this linker is made of 
five Gly residues at the C-terminus of the protein, whereas in our protein the linker is 
provided by six ethylene-glycol units in the hydrophilic portion of the lipid molecule 
(Scheme 1 in Materials and Methods). The independent results from both laboratories 
using different constructs of GPI-anchored PrP, show unequivocally that GPI-anchored 
prion protein, when reconstituted in POPC and raft membranes, retains the structural 
characteristics of PrP-WT in solution. Therefore, the results strongly suggest that when 
PrP is localised in phosphatidyl choline-rich lipid environments in the plasma membrane 
of neurons or within rafts in vivo, the protein has a similar structure to that of the soluble 
anchorless forms determined by NMR spectroscopy.  
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Prion conversion and membranes 
Cell biology studies implicate the plasma membrane surface as the likely site of prion 
conversion [19, 48, 49]. Since, the prion protein is predominantly localised within 
cholesterol and sphingomyelin-rich domains, or lipid rafts, in its cell-anchored form, it 
has been proposed that PrP conversion is likely to occur in rafts. Several lines of 
evidence implicate lipid rafts in prion conversion, but their precise role in this process is 
not fully understood and contradictory reports exist (reviewed in [50]). Some cell biology 
experiments appear to indicate that conversion could occur inside rafts whereas others 
support conversion outside rafts. The precise lipid environment experienced by PrP may 
be a crucial factor in prion pathogenesis. Recent studies have shown that the prion 
protein moves out of rafts before being endocytosed and rapidly recycled back to the 
cell surface [51]. This movement of PrP in and out of rafts exposes PrP to different lipid 
environments, which could affect the structure of PrP. Furthermore, prion plaques and 
aggregates extracted from diseased brains have been shown to contain lipids [52], 
which further supports the hypothesis that conversion must occur at the membrane 
surface and lipid may be involved in the actual molecular mechanism of prion 
conversion.  
A lipid-mediated conversion process of PrP is particularly relevant in sporadic 
cases of TSEs where, by as a yet unknown mechanism, the normal cellular form of PrP 
is spontaneously converted to aberrant aggregated forms associated with disease. An 
anomalous interaction of PrP with lipid could provide the initial unknown factor in 
spontaneous formation and subsequent accumulation of abnormal conformations of 
PrP. Therefore, in vitro studies employing a lipid-anchored prion molecule offer the 
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potential to unravel the effect of different lipid environments on prion structure and 
conversion. 
Previous studies have shown that anchorless forms of PrP can interact with 
various model lipid membranes and that this results in protein structural changes that 
lead to aggregation and/or fibrillization of PrP, depending on the lipid environment and 
starting conformation of the protein [33, 34]. The α-helical isoform of PrP, representing 
the cellular prion protein, can bind to raft membranes but this does not induce 
aggregation of PrP. In contrast, an altered β-sheet-rich form of PrP has a high affinity to 
raft membranes resulting in prion fibrillization. Binding of α-helical and β-sheet-rich 
forms of PrP to negatively charged lipids, typically found outside rafts in cell 
membranes, results in amorphous aggregation of prion proteins. These results, 
combined with the observed rapid transit of PrP in and out of rafts [51], have led us to 
propose that early steps in the conversion of PrP from its cellular, α-helical conformation 
to altered, β-sheet-rich states, prone to aggregation, may occur outside rafts [50]. Upon 
re-entry in rafts, β-sheet-rich forms of PrP have higher affinities to raft lipid components 
and aberrant prion molecules may start to accumulate within rafts, promoting protein-
protein interactions which ultimately result in aggregation and fibrillization of PrP.   
We have previously investigated the interaction of soluble, anchorless α-helical 
PrP with raft and POPC membranes. In these membranes, anchorless forms of prion 
proteins either do not directly interact with these lipids or if they do, no detrimental 
structural changes that would lead to aggregation are induced [34]. In the current study, 
insertion of lipid anchored construct PrP-GPIm into POPC and raft membranes results in 
protein that regains its α-helical structure and FTIR spectra of this protein are similar to 
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those of soluble constructs of anchorless PrP. The results suggest that the lipid raft 
environment protects the α-helical conformation of PrP, in line with our hypotheses that 
conversion is initiated outside rafts [50]. It remains to be tested whether reconstitution of 
anchored PrP-GPIm in a lipid environment that resembles that outside rafts alters the 
structure of PrP.  
Materials and methods 
Expression and purification of PrP 
The plasmid (pTrcSHaPrPMet23-231) encoding the Syrian hamster prion protein was 
prepared as described previously [53]. The mutant protein PrP-S231C was constructed 
by site directed mutagenesis of pTrcSHaPrPMet23-231 using a QuikChange® kit 
(Stratagene) according to the manufacturer's instructions. Briefly, the complimentary 
mutagenic primers (IDS12A, 5'-CGATGGAAGAAGGTGCTGAGAATTCGAAGC-3' and 
IDS12B, 5'-GCTTCGAATTCTCAGCACCTTCTTCCATCG-3') were synthesised and 
purified by MWG-Biotech AG to their “high purity salt free” (HPSF) standard. The 
mutagenesis reaction was performed in a thermal cycler using the following conditions: 1 
cycle of (30 s at 95 °C) and 15 cycles of (30 s at 95 °C, 1 min at 55 °C and 10 min at 68 
°C). Mutant clones were identified by DNA sequencing. The resulting plasmid will be 
referred to as pPrP-S231C.  
pPrP-S231C was used to transform the protease-deficient strain of E. coli, 
BL21Star (Invitrogen).  This strain had already been transformed with the Rosetta 
plasmid (Novagen), which codes for mammalian tRNAs that are rare or absent in E. coli. 
Transformed cells were grown overnight at 37 °C on Luria-Bertani (LB) agar containing 
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ampicillin (100 µg/mL) and chloramphenicol (37 µg/mL). A single colony was grown in 
LB medium until an absorbance of 0.6 at 600 nm was reached. Protein expression was 
then induced by the addition of 0.1 mM isopropyl-D-thiogalactopyranoside (IPTG) and 
the cells grown for a further 16 hours. PrP-S231C is expressed in inclusion bodies. Cells 
were harvested by centrifugation and disrupted by sonication. Inclusion bodies were 
isolated by centrifugation at 27,000 g for 30 minutes and washed twice in 25 mM Tris-
HCl pH 8.0, 5 mM EDTA.  The inclusion bodies were solubilized in 8 M guanidine 
hydrochloride, 25 mM Tris-HCl pH 8.0, 100 mM dithiothreitol. The solubilized reduced 
PrP-S231C was applied to a size exclusion column (Sephacryl S-300HR 26/60, 
Amersham Biosciences) and eluted in 6 M guanidine hydrochloride, 50 mM Tris-HCl pH 
8.0, 5 mM dithiothreitol, 1 mM EDTA. Fractions containing reduced PrP-S231C were 
then applied to a reverse-phase HPLC column (Poros R1 20, Applied Biosystems) and 
eluted in a water-acetonitrile gradient in the presence of 0.1% (v/v) trifluoroacetic acid. 
The purified, reduced PrP-S231C was lyophilised. Typically yields of 15-25 mg of 
reduced PrP-S231C per litre of culture were obtained.  
Oxidation of reduced PrP-S231C 
Formation of the native disulfide bond was carried out, using a method modified from Mo 
et al. [38]. Briefly, reduced PrP-S231C at a concentration of 1 mg/mL in 8 M guanidine 
hydrochloride, 25 mM Tris-HCl pH 8.0, was added drop-wise to 9 volumes of 50 mM 
Tris-HCl, 0.6 M L-arginine, 5 mM reduced glutathione, 0.5 mM oxidised glutathione pH 
8.5 and left stirring overnight at 4 °C. The sample was centrifuged at 4500 g at 4 °C for 
15 minutes to remove any precipitate and the supernatant was dialysed against 10 mM 
Tris-HCl pH 7.2. Precipitated protein (containing aggregated PrP) was removed using a 
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0.2 µm filter. The supernatant contained PrP with the native disulfide bond and 
glutathione protected C-terminal cysteine (Cys231). The glutathione protecting group on 
Cys231 was removed by treatment with 10 mM dithiothreitol for 10 minutes. The protein 
was applied to a reverse-phase HPLC column (Poros R1 20, Applied Biosystems) and 
eluted in a water-acetonitrile gradient in the presence of 0.1% (v/v) trifluoroacetic acid. 
The resulting purified PrP-React was lyophilised. The yield of the oxidation reaction 
followed by dialysis and subsequent removal of precipitated protein was typically 80% of 
the reduced protein obtained. This gave an overall yield of PrP-React of 12-20 mg per 
litre of culture.  
Synthesis of GPIm 
A mimetic of the GPI anchor (GPIm) was synthesised as detailed in Rullay, Hicks, 
Pinheiro and Crout (in preparation). GPIm contains two palmitoyl chains linked to a 
hexa-ethylene-glycol linker with a thiosulphonate reactive group (Scheme 1). The 
product was characterised by mass spectrometry and NMR.  
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Scheme 1. 3-(Hexadecane-1-sulfonyl)-2-(hexadecane-1-sulfonylmethyl) propionic acid 
2-[2-(2-{2-[2-(2-methanesulfonylsulfanylethoxy)ethoxy]ethoxy}ethoxy)ethoxy] ethyl ester 
Coupling reaction between PrP-React and GPIm 
One volume of a concentrated solution (250 µM) of PrP-React in water was added to 
nine volumes of GPIm in an ethanol/water solution, resulting in a reaction mixture 
containing  70% ethanol in water (v/v) and a 10-fold molar excess of GPIm relative to 
PrP-React ([GPIm] = 250 µM; [PrP-React] = 25 µM). The solution was stirred for 2 hours 
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at room temperature and applied to a reverse-phase HPLC column (Poros R1 20, 
Applied Biosystems). The product, GPIm-modified protein (PrP-GPIm), was separated 
from unmodified protein on a water-acetonitrile gradient in the presence of 0.1% TFA.  
Liquid chromatography mass spectrometry (LC-MS) 
All mass spectrometry was performed in the Proteomics Facility at the Institute for 
Animal Health as previously described [43]. Briefly, proteinaceous samples were 
analysed by online capillary HPLC (180 µm i.d., 5 µm bead size, 300 Å pore size, Jupiter 
C18, Phenomenex, Macclesfield, UK). Retained components were eluted from the home-
packed column by an increasing gradient of solvent B, where solvent A was 95:5 
H2O:acetonitrile with 0.05 % trifluoroacetic acid (TFA) and solvent B was 5:95 
H2O:acetonitrile with 0.05 % TFA. Prior to analysis, samples were diluted with solvent A 
to approximately 1 pmole/µl and around 20 pmole of total protein was injected onto a 
homemade pre-concentration trap for initial desalting. The HPLC eluate was passed 
directly to a Quattro II mass spectrometer (Waters UK Ltd) equipped with a continuous-
flow nanospray source. The mass spectrometer was operated in positive ion mode and 
acquired full scan mass spectra (m/z 300-2100) every 5 seconds.  
Liposome preparation 
Single lipids or mixtures of lipids were mixed in chloroform solution and dried under 
nitrogen to form lipid films. The films were further dried overnight under vacuum to 
remove residual chloroform. Vesicles were prepared in 2 mM 2-(N-
morpholino)ethanesulphonic acid (MES) at pH 5 or pH7 containing either POPC only, or 
a mixture of dipalmitoyl phosphatidylcholine (DPPC), cholesterol (chol) and 
sphingomyelin (SM) at a molar ratio of 5:3:2. Mixed DPPC/chol/SM (5:3:2) vesicles 
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represent the composition of chol- and SM-rich domains in the plasma membrane, 
known as rafts,  and are referred to here as raft membranes. The aqueous buffer was 
flushed with nitrogen prior to hydration of the lipid film. To break multilamellar vesicles, 
the hydrated lipid samples were subjected to five cycles of freezing and thawing (under 
nitrogen) using a dry ice-ethanol mixture and a 55 °C water bath. Vesicles were 
extruded ten times through two 200nm polycarbonate membranes under nitrogen at a 
pressure of 150psi and a temperature of 55 °C in a stainless steel extrusion device 
(Lipex Biomembranes, Vancouver). The size of the liposomes was measured at 20 °C 
by dynamic light scattering on a DynaPro molecular sizing instrument (Hampton 
Research, Aliso Viejo CA) and was found to be similar to the pore size of the membrane 
used for the extrusion process. The change in the size and polydispersity of the 
liposomes was minimal after 10 extrusion cycles [54].  
Reconstitution of PrP-GPIm into liposomes 
Liposomes were titrated at 20 °C with the detergent octyl-β-D-glucopyranoside (OG) 
(Fluka) and light scattering at 350 nm was followed in a spectrophotometer. The 
midpoint of solubilization for the liposomes was determined. This concentration of OG 
was used in the reconstitution of PrP-GPIm into liposomes. PrP-GPIm was mixed with 
the appropriate amount of OG and sonicated for 15 minutes in a water bath at room 
temperature. Liposomes were added to yield final concentrations of: PrP-GPIm 10µM, 
total lipid 1mM, OG 22mM – 28mM (depending on lipids used), in 2 mM MES buffer at 
pH 5 or 7. The mixture was placed in a sonicating water bath and sonicated twice at 
room temperature for 15 minutes. Samples were kept at room temperature for a further 
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30 minutes. OG was removed by extensive dialysis at room temperature against 2 mM 
MES buffer at pH 5 or 7.  
The incorporation of PrP-GPIm into liposomes was assayed using sucrose gradient 
centrifugation. Discontinuous sucrose gradients were prepared, where reconstituted 
PrP-GPIm in lipid vesicles was adjusted to 40 % sucrose and overlaid with a 30 % 
sucrose layer followed by a 5 % sucrose layer. The samples were spun at 140,000 g in 
a Beckman SW50.1 rotor at 4 °C for 16 hrs. Eight fractions spanning the entire gradient 
were taken from the top and analysed by SDS-PAGE to detect protein-containing 
fractions. Lipid-containing fractions were identified by turbidity and dialysed against 2 
mM MES at pH 5 or 7 to remove the sucrose. Liposomes were harvested by 
centrifugation at 140,000 g in a Beckman SW50.1 rotor at 4 °C for 1 h. The supernatant 
was discarded and the liposomes re-suspended in ¼ of the original volume of the 
reconstitution mixture in 2 mM MES at pH 5 or 7.  
Circular dichroism spectroscopy 
Circular dichroism (CD) spectra were collected at room temperature (21 °C) using a 0.1 
cm path length quartz cuvette (Starna brand, Optiglass Ltd., Hainault) in a Jasco J-715 
spectropolarimeter (Jasco UK, Great Dunmow). The bandwidth was 2 nm and the 
scanning speed was 200 nm.min−1 with a response time of 1 second and a data pitch of 
0.5 nm. Typically, 16 spectra were averaged and buffer baselines were subtracted from 
the data.  
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ATR FTIR 
Liposomes were deposited on a germanium internal reflection element (IRE) and dried 
under nitrogen. Spectra were measured using a Vector 22 instrument (Bruker) fitted with 
a mercury cadmium telluride (MCT) detector. Data are at a resolution of 4 cm−1 and are 
an average of 1024 spectra collected at room temperature (21 °C). The water vapour 
signal was removed from the spectra and peak fitting was performed using GRAMS AI 
software (ThermoGalactic, Salem). Lorentzian curves were fitted to the amide I band of 
the PrP signal and assigned to a secondary structure type according to Byler and Susi 
[55].  
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Figure legends 
Fig. 1.  Schematic diagram of PrP-GPIm anchored in a lipid membrane. The mimetic 
GPI anchor (GPIm) is shown in orange coupled via a disulfide bond (S-S) to a Cys 
residue at the C-terminus at the end of helix C in PrP. The lipid membrane is 
represented by a fragment of a bilayer formed by ideally packed lipid molecules, 
comprising a hydrophilic head group (dark-blue circles) and hydrophobic acyl chains 
(yellow tails). The folded C-terminal domain of the protein shows the 3 helices in red (A, 
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B, C) and the small anti-parallel β-sheet in green [41]. The N-terminal portion (residues 
23−126) has no defined, high resolution structure and is shown schematically in light-
blue with N labelling the N-terminus. The internal disulfide bond between the two main 
helices (B and C) is shown in yellow.  
Fig. 2.  Mass spectrometric characterisation and HPLC separation of refolded states of 
PrP-S231C. (A) Electrospray mass spectrum and (inset) deconvoluted mass spectrum 
of PrP-Glut after refolding of PrP-S231C in the presence of glutathione. The measured 
mass (23,424.6 Da) is in good agreement with the calculated mass (23,423.9 Da) for 
PrP with an intact internal disulfide bond and a modified C-terminal Cys 231 residue with 
a single glutathione molecule. (B) HPLC purification of PrP-Glut after treatment with the 
reducing agent DTT to give PrP-React. The main peak is the desired product and the 
smaller shoulder is fully reduced material that was discarded by peak cutting. (C) 
Electrospray mass spectrum and (inset) deconvoluted mass spectrum of PrP-React. The 
measured mass (23,119.3 Da) agrees with the calculated mass (23,118.6 Da) for PrP 
with an internal disulfide bond and the presence of a free thiol group on Cys 231.  
Fig. 3. Solubility and reactivity of the lipid anchor GPIm in ethanol / water mixtures.  
(A) The solubility in ethanol / water mixtures was monitored by light scattering at 450 
nm. Insoluble GPIm creates a suspension that scatters light and gives a large signal. As 
the ethanol concentration increases the GPIm stays in solution and therefore scatters 
less light and gives a smaller signal. (B) The efficiency of the coupling reaction between 
PrP-React and GPIm was monitored by peak area of the product on an HPLC gradient. 
Maximal product was obtained around 70% ethanol.  
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Fig. 4. HPLC purification and MS characterisation of PrP-GPIm. (A) After reaction of 
PrP-React with GPIm, the product PrP-GPIm was purified by RP-HPLC. The product 
elutes as a broad peak at around 220 seconds and uncoupled material elutes at around 
180 seconds. (B) Electrospray mass spectrum and (inset) deconvoluted mass spectrum 
of PrP-GPIm. The measured mass of 24,064.3 Da agrees with the expected calculated 
mass of 24,064.1 Da.  
Fig. 5. Solubilization of liposomes by the detergent octyl-β-D-glucopyranoside (OG) at 
20 °C. Liposomes formed by extrusion at pH 7 (open circles) and at pH 5 (filled circles) 
were titrated with OG and the turbidity was monitored at 350 nm. The drop in turbidity 
above 20 mM OG represents the detergent-solubilization of liposomes. (A) POPC 
liposomes at pH 7 (open circles) and pH 5 (filled circles). (B) The process was repeated 
for raft liposomes at pH 7 (open circles) and at pH 5 (filled circles).  
Fig. 6. SDS-PAGE of fractions from density gradient separation of reconstitutions of 
PrP-GPIm in lipid membranes. Membrane reconstitutions of PrP-GPIm were separated 
on sucrose step gradients and 8 fractions spanning the entire sucrose gradient were 
collected from top-to-bottom. The fractions were analyzed for protein by SDS-PAGE. 
From left-to-right the lanes are markers (M) and the eight fractions (labelled 1 to 8) from 
the gradient. Samples of PrP-GPIm were reconstituted into vesicles containing (A) 
POPC at pH 5, (B) POPC at pH 7, (C) rafts at pH 5 and (D) rafts at pH 7. Lipid was 
visible in fractions 1 to 3 for POPC (A and B) and in fraction 3 for raft lipids (C and D). 
The majority of the protein co-migrated with the liposomes in the sucrose gradient.  
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Fig. 7. Structure of PrP-GPIm compared with PrP-WT in solution. (A) Far-UV CD 
spectra of PrP-WT (solid line) and PrP-GPIm (dashed line) in solution at pH 5. (B) The 
amide I region of ATR FTIR spectra of PrP-WT (solid line) and PrP-GPIm (dashed line) 
in solution at pH 5 compared with PrP-GPIm after reconstitution into POPC (dash-dot 
line) and raft membranes (dash-dot-dot line) at pH 5. 
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